A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer

被引：0
|
作者：
Pin Zhang
Binghe Xu
Lin Gui
Wenna Wang
Meng Xiu
Xiao Zhang
Guilan Sun
Xiaoyu Zhu
Jianjun Zou
机构：
[1] National Cancer Center/Cancer Hospital,
[2] Chinese Academy of Medical Sciences and Peking Union Medical College,undefined
[3] Jiangsu Hengrui Medicine Co. Ltd,undefined
来源：
Biomarker Research | / 9卷
关键词：
Cyclin-dependent kinase 4/6 inhibitor; Advanced breast cancer; First-in-human trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Macrocytosis and dysplastic anemia is associated with the cyclin-dependent kinase 4/6 inhibitor palbociclib in metastatic breast cancer
    Anampa, Jesus
    Haque, Tamanna
    Murakhovskaya, Irina
    Wang, Yanhua
    Bachiashvili, Kimo
    Papazoglu, Cristian
    Pradhan, Kith
    Steidl, Ulrich G.
    Sparano, Joseph A.
    Verma, Amit
    HAEMATOLOGICA, 2018, 103 (03) : E98 - E102
  • [32] Cyclin-Dependent Kinase 4/6 Inhibitor (Palbociclib) Induced Aplastic Anemia in a Patient with Metastatic Breast Cancer
    Nwabudike, Stanley Madu
    Edwards, Camille V.
    Akinboro, Oladimeji
    Quinn, Kathryn
    Sarosiek, Shayna
    Ko, Naomi
    CASE REPORTS IN HEMATOLOGY, 2018, 2018
  • [33] Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy
    Tan, AR
    Swain, SM
    SEMINARS IN ONCOLOGY, 2002, 29 (03) : 77 - 85
  • [34] Cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced oestrogen receptor-positive breast cancer
    Dubianski, Roman
    Jagiello-Gruszfeld, Agnieszka
    Nowecki, Zbigniew
    ONCOLOGY IN CLINICAL PRACTICE, 2016, 12 (06): : 209 - 214
  • [35] Cyclin-dependent kinase 4 inhibitor a and tumor
    Gong, Z.
    Fu, J.
    Chinese Journal of Medical Genetics, 2001, 18 (03) : 219 - 221
  • [36] Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer
    Tan, AR
    Yang, XW
    Berman, A
    Zhai, SP
    Sparreboom, A
    Parr, AL
    Chow, C
    Brahim, JS
    Steinberg, SM
    Figg, WD
    Swain, SM
    CLINICAL CANCER RESEARCH, 2004, 10 (15) : 5038 - 5047
  • [37] Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6
    Toogood, PL
    Harvey, PJ
    Repine, JT
    Sheehan, DJ
    VanderWel, SN
    Zhou, HR
    Keller, PR
    McNamara, DJ
    Sherry, D
    Zhu, T
    Brodfuehrer, J
    Choi, C
    Barvian, MR
    Fry, DW
    JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (07) : 2388 - 2406
  • [38] Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors
    Schwartz, GK
    O'Reilly, E
    Ilson, D
    Saltz, L
    Sharma, S
    Tong, W
    Maslak, P
    Stoltz, M
    Eden, L
    Perkins, P
    Endres, S
    Barazzoul, J
    Spriggs, D
    Kelsen, D
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (08) : 2157 - 2170
  • [39] Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib
    Dorota Kwapisz
    Breast Cancer Research and Treatment, 2017, 166 : 41 - 54
  • [40] Cyclin-Dependent Kinase 4/6=Inhibitor Outcomes in Patients With Advanced Breast Cancer Carrying Germline Pathogenic Variants in DNA Repair-Related Genes
    Bruno, Luisina
    Ostinelli, Alexis
    Waisberg, Federico
    Enrico, Diego
    Ponce, Carolina
    Rivero, Sergio
    Blanco, Albano
    Zarba, Martin
    Loza, Martin
    Fabiano, Veronica
    Amat, Mora
    Teresa Pombo, Maria
    Noro, Laura
    ChacOn, Matias
    ColO, Federico
    ChacOn, Reinaldo
    Nadal, Jorge
    Nervo, Adriin
    Costanzo, Victoria
    JCO PRECISION ONCOLOGY, 2022, 6
12345